Year: 2019
Type: article
Abstract: Malignant melanoma is one of the most difficult cancers to treat due to its resistance to chemotherapy. Despite recent successes with BRAF inhibitors and immune checkpoint inhibitors, many patients do not respond or become resistant to these drugs. Hence, alternative treatments are still required. Due to the importance of the BCL-2-regulated apoptosis pathway in cancer development and drug resistance, it is of interest to establish which proteins are most important for melanoma cell survival, though the outcomes of previous studies have been conflicting. To conclusively address this question, we tested a panel of established and early passage patient-derived cell lines against several BH3-mimetic drugs designed to target individual or subsets of pro-survival BCL-2 proteins, alone and in combination, in both 2D and 3D cell cultures. None of the drugs demonstrated significant activity as single agents, though combinations targeting MCL-1 plus BCL-XL, and to a lesser extent BCL-2, showed considerable synergistic killing activity that was elicited via both BAX and BAK. Genetic deletion of BFL-1 in cell lines that express it at relatively high levels only had minor impact on BH3-mimetic drug sensitivity, suggesting it is not a critical pro-survival protein in melanoma. Combinations of MCL-1 inhibitors with BRAF inhibitors also caused only minimal additional melanoma cell killing over each drug alone, whilst combinations with the proteasome inhibitor bortezomib was more effective in multiple cell lines. Our data show for the first time that therapies targeting specific combinations of BCL-2 pro-survival proteins, namely MCL-1 plus BCL-XL and MCL-1 plus BCL-2, could have significant benefit for the treatment of melanoma.
Source: Cell Death and Disease
Authors: Erinna F. Lee, Tiffany J. Harris, Sharon Tran, Marco Evangelista, Surein Arulananda, Thomas John, Celeste Ramnac, Chloe Hobbs, Haoran Zhu, Gency Gunasingh, David Segal, Andreas Behren, Jonathan Cebon, Alexander Dobrovic, John M. Mariadason, Andreas Strasser, Leona Rohrbeck, Nikolas K. Haass, Marco J. Herold, W. Douglas Fairlie
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $3,760
Funders: U.S. Department of Health and Human Services, Cancer Research Institute, Victorian Cancer Agency, Australian Government, Peter MacCallum Cancer Centre, State Government of Victoria, Worldwide Cancer Research, Department of Education and Training, Medical Research Council, Australian Research Council, National Health and Medical Research Council
Awards: Crosstalk between cell survival and cell death pathways, G2236554835, Elucidating the cellular processes that are critical for p53 mediated tumour suppression, Apoptosis and Stem Cells in Cancer, Examining the contribution of mutant DNMT3a in the development and sustained growth of Acute Myeloid Leukaemia, G7283855729, G767223762, G7679995401, Research Fellowship, G8996902947
OpenAlex ID: W2942007182
